摘要
阐述近年来心房颤动抗凝药物的研究进展。2010年ESC房颤治疗指南强调了抗凝治疗的重要性。华法林因为其出血风险高,治疗窗狭窄和需要常规检测凝血酶原时间国际标准化比值(INR),所以使用时存在许多局限性。正在进行房颤抗凝治疗临床评价的新型抗凝药包括达比加群酯、AZD0837、利伐沙班、阿哌沙班等对房颤患者卒中和全身性血栓栓塞的预防效果不劣于华法林,并且使用更简便、安全,展现了良好的发展前景。
This article summarized some progress in anticoagulation therapy in atrial fibrillation. Guidelines for the management of atrial fibrillation published by ESC in 2010 underlined the importance of anticoagulation therapy. Used within the recommended therapeutic range, warfarin remains under-used, because of the perceived high risk of hemorrhage, narrow therapeutic window and need for regular monitoring INR. Several novel anti-coagulants show promise in anticoagulation therapy of atrial fibrillation. In particular, Dabigatran etexilate, AZD0837, Rivaroxaban and Apixaban are noninferior to warfarin for the prevention of stroke or systemic embolism, although they are receiving Chnical assessments.
出处
《心血管病防治知识（学术版）》
2012年第5期36-41,共6页
Prevention and Treatment of Cardiovascular Disease
